In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potenza Therapeutics Inc.

Division of Astellas Pharma Inc.
http://potenzatherapeutics.com/

Latest From Potenza Therapeutics Inc.

Enfortumab Vedotin Impresses In Urothelial Cancer After Chemo, Immunotherapies

The antibody-drug conjugate being evaluated by Astellas and Seattle Genetics has posted “remarkable” positive top-line results in locally advanced or metastatic urothelial cancer, with a US BLA submission expected later in 2019.

 

Cancer Clinical Trials

MPM Raises $400m To Build Early-Stage Biotechs

The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.

Financing ImmunoOncology

Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis

As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period… 

Japan 2018 Review: Takeda/Shire Dominates But Pharma Life Goes On

2018 in Japan wasn't all about Takeda and Shire - though it mostly was. Amid a generally quiet year for M&A otherwise, companies concentrated on honing their specialty focus, dealing with major patent expiries, and fretting about big changes to the country's pricing system.

Japan Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Astellas Pharma Inc.
  • Senior Management
  • Daniel J Hicklin, PhD, Pres. & CEO
  • Contact Info
  • Potenza Therapeutics Inc.
    Phone: (617) 588-4150
    1030 Massachusetts Ave., Ste. 210
    Cambridge, MA 02138
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register